Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Namodenoson

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Can-Fite’s Namodenoson Treats Esophageal Varices in Cirrhosis
    Can-Fite’s Namodenoson Treats Esophageal Varices in Cirrhosis

    15 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/15/3149846/0/en/Can-Fite-Reports-Complete-Resolution-of-Esophageal-Varices-in-Decompensated-Cirrhosis-Patient-Treated-with-Namodenoson.html

    GLOBENEWSWIRE
    15 Sep 2025
    Share Share
    Can-Fite's Namodenoson Hits 50% Enrollment in Phase 2a Study
    Can-Fite's Namodenoson Hits 50% Enrollment in Phase 2a Study

    30 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/30/3123927/0/en/Pancreatic-Cancer-Phase-2a-Study-with-Can-Fite-s-Namodenoson-Achieved-Over-50-Enrollment-Milestone.html

    GLOBENEWSWIRE
    30 Jul 2025
    Share Share
    U.S. Medical Centers Seek Authorization for Namodenoson
    U.S. Medical Centers Seek Authorization for Namodenoson

    17 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/17/3063424/0/en/Following-FDA-Compassionate-Use-Approval-for-Pancreatic-Carcinoma-with-Can-Fite-s-Namodenoson-Leading-U-S-Medical-Centers-Seek-Authorization-for-their-Patients.html

    GLOBENEWSWIRE
    17 Apr 2025
    Share Share
    Can-Fite: FDA Approves Use of Namodenoson in Pancreatic Cancer
    Can-Fite: FDA Approves Use of Namodenoson in Pancreatic Cancer

    18 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/18/3044514/0/en/Can-Fite-FDA-Approved-Compassionate-Use-Treatment-with-Namodenoson-in-a-Pancreatic-Cancer-Patient.html

    GLOBENEWSWIRE
    18 Mar 2025
    Share Share
    Can-Fite Publishes Namodenoson Benefits In Liver Cancer
    Can-Fite Publishes Namodenoson Benefits In Liver Cancer

    03 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/03/3035375/0/en/Can-Fite-Innovative-Publication-Namodenoson-in-Liver-Cancer-Treatment-Alongside-with-Cardiac-Liver-and-Neurological-Benefits.html

    GLOBENEWSWIRE
    03 Mar 2025
    Share Share
    Can-Fite’s Namodenoson Clears Decompensated Liver Cirrhosis
    Can-Fite’s Namodenoson Clears Decompensated Liver Cirrhosis

    18 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/18/3027671/0/en/Disappearance-of-Decompensated-Liver-Cirrhosis-Episodes-After-Treatment-with-Can-Fite-s-Namodenoson.html

    GLOBENEWSWIRE
    18 Feb 2025
    Share Share